Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

Launched by EMS · Aug 25, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called Piemonte association for people with type 2 diabetes mellitus. The main goal is to see if this treatment is effective and safe for patients who have struggled to manage their blood sugar levels despite trying diet changes, exercise, and other medications over the past three months.

To participate, individuals must be between the ages of 65 and 74 and have a confirmed diagnosis of type 2 diabetes. They should also be willing to sign a consent form to show they understand and agree to join the study. However, not everyone can take part; for example, those with certain health issues or those who have been pregnant or breastfeeding recently are excluded. Participants will be monitored throughout the study to ensure their safety and to gather important information about how well the treatment works. This study is not yet recruiting participants, but it aims to provide valuable insights into diabetes management.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the consent form;
• • Diagnosis of type II diabetes mellitus, and who did not reach the therapeutic goal of HbA1c with previous dietary, physical exercise, and previous therapies at stable doses within 3 months.
• Exclusion Criteria:
• • Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of participants;
• • History of alcohol abuse or illicit drug use;
• • Participation in a clinical trial in the year prior to this study;
• • Pregnancy or risk of pregnacy and lactating participants;
• • Known hypersensitivity to any of the formula compounds;
• • Type 1 diabetes.